IHT Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

IHT Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-28	Closed	-$1K	–	1049
2018 Q1	$1K	Hold	28	–	–	﹤0.01%	1612
2017 Q4	$2K	Buy	28 +18	+180%	+$2.03K	﹤0.01%	1502
2017 Q3	$1K	Hold	10	–	–	﹤0.01%	1336
2017 Q2	$386	Hold	10	–	–	0.19%	135
2017 Q1	$1K	Buy	10 +5	+100%	+$577	﹤0.01%	1197
2016 Q4	$1K	Buy	+5	New	+$551	﹤0.01%	1141

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WJA

Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

IHT Wealth Management's IMDX Position: Q2 2018 in Review

IHT Wealth Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2018, closing a stake of 28 shares — an estimated $1K sold.

IHT Wealth Management first reported a position in IMDX in Q4 2016 and held it in 6 quarters. The position peaked at $2K in Q4 2017. 33 funds tracked by Wall St. Rank hold IMDX as of Q2 2018.

IHT Wealth Management reported no remaining Insight Molecular Diagnostics position as of Q2 2018 after selling out during the quarter.
IHT Wealth Management sold 28 Insight Molecular Diagnostics shares in Q2 2018, an estimated $1K.
IHT Wealth Management first reported a position in Insight Molecular Diagnostics in Q4 2016 and held it in 6 quarters.
IHT Wealth Management's Insight Molecular Diagnostics position peaked at $2K in Q4 2017.
33 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.